• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

表皮生长因子受体（EGFR）突变型肺腺癌中的小细胞与鳞状细胞联合转化

Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma.

作者信息

Hakozaki Taiki, Kitazono Miyako, Takamori Mikio, Kiriu Takahiro

机构信息

Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan.

Department of Respiratory Medicine and Medical Oncology, Tokyo Metropolitan Tama Medical Center, Japan.

出版信息

Intern Med. 2020 May 15;59(10):1291-1294. doi: 10.2169/internalmedicine.3542-19. Epub 2020 Feb 26.

DOI:10.2169/internalmedicine.3542-19
PMID:32101830
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7303443/
Abstract

Histologic transformation has been described as an acquired mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). We herein report the case of a woman with stage IV lung adenocarcinoma harboring EGFR exon 19 deletions who was initially treated with EGFR-TKIs; several cytotoxic chemotherapeutic regimens were used when resistance developed. A lymph node re-biopsy revealed histologic transformation of the tumor to combined small-cell lung cancer and squamous cell carcinoma with retained EGFR exon 19 deletions. Following sequential chemotherapy appropriate for transformed histology, a clinical response was achieved.

摘要

组织学转化已被描述为对表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）产生耐药的一种获得性机制。我们在此报告一例IV期肺腺癌女性患者，该患者存在EGFR第19外显子缺失，最初接受EGFR-TKIs治疗；耐药发生后使用了几种细胞毒性化疗方案。淋巴结再次活检显示肿瘤组织学转化为小细胞肺癌和鳞状细胞癌合并存在，EGFR第19外显子缺失依然存在。采用适合转化后组织学类型的序贯化疗后，取得了临床缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec4/7303443/be4e739b8f77/1349-7235-59-1291-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec4/7303443/2748530d359b/1349-7235-59-1291-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec4/7303443/5e8294907c4b/1349-7235-59-1291-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec4/7303443/be4e739b8f77/1349-7235-59-1291-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec4/7303443/2748530d359b/1349-7235-59-1291-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec4/7303443/5e8294907c4b/1349-7235-59-1291-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec4/7303443/be4e739b8f77/1349-7235-59-1291-g003.jpg

相似文献

1
Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma.表皮生长因子受体（EGFR）突变型肺腺癌中的小细胞与鳞状细胞联合转化
Intern Med. 2020 May 15;59(10):1291-1294. doi: 10.2169/internalmedicine.3542-19. Epub 2020 Feb 26.
2
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.一例发生鳞状细胞癌转化的表皮生长因子受体（EGFR）突变型肺腺癌对阿法替尼表现出持久反应。
Intern Med. 2018 Dec 1;57(23):3429-3432. doi: 10.2169/internalmedicine.0999-18. Epub 2018 Aug 10.
3
Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.表皮生长因子受体（EGFR）突变型肺腺癌中转化为小细胞肺癌作为一种获得性耐药机制：对依托泊苷和顺铂完全缓解的病例报告
Tumori. 2015 Jun 25;101(3):e96-8. doi: 10.5301/tj.5000276.
4
Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.非小细胞肺癌患者来源异种移植模型用于评估靶向药物敏感性和耐药性。
Cancer Sci. 2019 Oct;110(10):3215-3224. doi: 10.1111/cas.14171.
5
Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.源自具有突变表皮生长因子受体的腺癌的小细胞肺癌揭示了肿瘤细胞转录改变的特征。
Intern Med. 2019 Nov 15;58(22):3261-3265. doi: 10.2169/internalmedicine.2988-19. Epub 2019 Jul 10.
6
Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review.从 EGFR 突变型肺腺癌转化为小细胞肺癌：病例报告及文献复习。
Cancer Biol Ther. 2018 Jun 3;19(6):445-449. doi: 10.1080/15384047.2018.1435222. Epub 2018 Mar 6.
7
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.表皮生长因子受体突变型肺腺癌中鳞状细胞癌“转化”和 EGFR 外显子 20 S768I 突变的同步发生是一种新的耐药机制。
Lung Cancer. 2017 Jan;103:24-26. doi: 10.1016/j.lungcan.2016.11.012. Epub 2016 Nov 17.
8
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.肺腺癌初始携带有敏感 EGFR 突变，一线吉非替尼和二线细胞毒化疗获得性耐药。
BMC Pharmacol Toxicol. 2017 May 10;18(1):21. doi: 10.1186/s40360-017-0130-0.
9
Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.病例报告：一名肺腺癌患者在接受表皮生长因子受体酪氨酸激酶抑制剂维持治疗后发生小细胞转化并转移至乳腺。
BMC Cancer. 2016 Aug 3;16:593. doi: 10.1186/s12885-016-2623-4.
10
Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma.一名肺腺癌患者在接受吉非替尼和放疗后发生组织学转化为小细胞肺癌。
Tumori. 2019 Dec;105(6):NP12-NP16. doi: 10.1177/0300891619832261. Epub 2019 Feb 24.

引用本文的文献

1
Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation.揭示肺腺鳞癌转化中的免疫机制和治疗靶点。
Front Immunol. 2025 Jun 3;16:1542526. doi: 10.3389/fimmu.2025.1542526. eCollection 2025.
2
Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the Gene.克服非小细胞肺癌患者基因发生突变后对奥希替尼耐药的可能性。
Cancers (Basel). 2025 Feb 7;17(4):563. doi: 10.3390/cancers17040563.
3
Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.

本文引用的文献

1
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case.表皮生长因子受体突变型肺腺癌患者接受酪氨酸激酶抑制剂治疗后出现表型改变为鳞状细胞癌的结局：一项荟萃分析及附加病例报告。
Lung Cancer. 2019 Jan;127:12-18. doi: 10.1016/j.lungcan.2018.11.016. Epub 2018 Nov 13.
2
Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report.吉非替尼治疗后腺癌组织学转化为小细胞肺癌和鳞状细胞癌：一例报告。
Medicine (Baltimore). 2018 May;97(18):e0650. doi: 10.1097/MD.0000000000010650.
3
优化奥希替尼用于非小细胞肺癌的治疗：靶向耐药性并探索联合疗法。
Cancers (Basel). 2025 Jan 29;17(3):459. doi: 10.3390/cancers17030459.
4
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options.奥希替尼耐药：分子机制与新出现的治疗选择
Cancers (Basel). 2023 Jan 30;15(3):841. doi: 10.3390/cancers15030841.
5
Acquired Resistance to Osimertinib in -Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?奥希替尼耐药的 - 突变型非小细胞肺癌：我们如何克服它？
Int J Mol Sci. 2022 Jun 22;23(13):6936. doi: 10.3390/ijms23136936.
6
Transformation from Small Cell to Squamous Cell Carcinoma in a Thymic Carcinoma Patient with a Durable Response to Anlotinib: A Case Report.一例对安罗替尼产生持久反应的胸腺癌患者从小细胞癌转化为鳞状细胞癌：病例报告
Cancer Manag Res. 2022 Apr 29;14:1595-1602. doi: 10.2147/CMAR.S362858. eCollection 2022.
7
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.癌基因依赖型非小细胞肺癌的形态-分子转化。
Int J Mol Sci. 2022 Apr 9;23(8):4164. doi: 10.3390/ijms23084164.
8
Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.靶向表皮生长因子受体突变型非小细胞肺癌的获得性和内在耐药机制。
Drugs. 2022 Apr;82(6):649-662. doi: 10.1007/s40265-022-01698-z. Epub 2022 Apr 12.
9
Overcoming therapy resistance in EGFR-mutant lung cancer.克服 EGFR 突变型肺癌的治疗抵抗。
Nat Cancer. 2021 Apr;2(4):377-391. doi: 10.1038/s43018-021-00195-8. Epub 2021 Apr 15.
10
Treatments for combined small cell lung cancer patients.小细胞肺癌合并症患者的治疗方法。
Transl Lung Cancer Res. 2020 Oct;9(5):1785-1794. doi: 10.21037/tlcr-20-437.
Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review.
表皮生长因子受体（EGFR）突变型肺腺癌转化为鳞状细胞癌：1例报告及文献复习
Clin Lung Cancer. 2018 Jan;19(1):e63-e66. doi: 10.1016/j.cllc.2017.10.005. Epub 2017 Oct 19.
4
Squamous cell transformation and T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report.肺腺癌患者接受酪氨酸激酶抑制剂治疗后出现鳞状细胞转化和T790M突变作为获得性耐药机制：一例报告
Oncol Lett. 2017 Nov;14(5):5947-5951. doi: 10.3892/ol.2017.6913. Epub 2017 Sep 8.
5
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.肺腺癌演变为小细胞癌的克隆进化史和遗传预测因子。
J Clin Oncol. 2017 Sep 10;35(26):3065-3074. doi: 10.1200/JCO.2016.71.9096. Epub 2017 May 12.
6
Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.未经表皮生长因子受体（EGFR）抑制治疗的EGFR突变型肺腺癌的组织学转化
Lung Cancer. 2017 Mar;105:14-16. doi: 10.1016/j.lungcan.2017.01.005. Epub 2017 Jan 11.
7
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.达沙替尼对肺癌细胞中 EMT 介导的 EGFR 抑制剂耐药机制的影响。
Lung Cancer. 2017 Feb;104:85-90. doi: 10.1016/j.lungcan.2016.12.012. Epub 2016 Dec 21.
8
TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.TOPK通过磷酸化并激活c-Jun来促进肺癌对EGFR酪氨酸激酶抑制剂的耐药性。
Oncotarget. 2016 Feb 9;7(6):6748-64. doi: 10.18632/oncotarget.6826.
9
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.非小细胞肺癌患者的表皮生长因子受体酪氨酸激酶抑制剂耐药性：机制与策略
Am J Cancer Res. 2014 Sep 6;4(5):411-35. eCollection 2014.
10
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.曲妥珠单抗-恩杂鲁胺对HER-2过表达的非小细胞肺癌细胞系具有活性，并克服了吉非替尼耐药性。
Mol Cancer. 2014 Jun 5;13:143. doi: 10.1186/1476-4598-13-143.